Compare Quest Diagnostics Inc (DGX) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ecolab Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Ecolab Inc. trades at $281.83 (market cap $78.97B). The key difference: Ecolab Inc. is far larger — about 3.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Ecolab Inc. for 90 Days on average.
| DGX | ECL | |
|---|---|---|
Market Cap | $25.48B | $78.97B |
Volume | 941,866 | 974,947 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $308.35 |
52-Week Low | $173.49 | $245.73 |
Typical Hold Time | 56 Days | 90 Days |
Enterprise Value | $31.23B | $87.75B |
Dividend Yield | 1.49% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
ECL trades at $281.83, up 1.34% today, with strong analyst support (78% buy ratings) and a $326.38 consensus price target. The stock shows bullish technical momentum above key support at $279, while fundamentals reveal steady revenue growth to $16.08B in 2025 and robust profitability with 12.57% net margins. Recent Q2 earnings beat expectations, and the company maintains dividend aristocrat status with consistent payout increases.
Outlook remains positive given ECL's essential service contracts, digital segment growth, and high institutional ownership. Key risks include rising debt from the $4.75B CoolIT acquisition and cost inflation pressures. The stock offers a compelling growth-and-income profile for investors seeking exposure to defensive industrial services with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
